Abstract
According to the previously reported potent dual l-peptide PMI of p53-MDM2/MDMX interactions, a series of d-amino acid mutational PMI analogues, PMI-1-4, with enhanced proteolytic resistence and in vitro tumor cell inhibitory activities were reported, of which Liposome-PMI-1 showed a stronger inhibitory activity against the U87 cell lines than Nutlin-3. This d-amino acid mutation strategy may give a hand for enhancing the potential of peptide drugs.
Keywords:
MDM2/MDMX; P53; PMI; Peptides; Tumor; d-Amino acid.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Amino Acids / metabolism
-
Binding Sites
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Cell Survival
-
Circular Dichroism
-
Humans
-
Liposomes / chemistry
-
Molecular Dynamics Simulation
-
Peptide Library
-
Peptides / chemistry
-
Peptides / metabolism*
-
Peptides / pharmacology
-
Protein Interaction Domains and Motifs / drug effects
-
Protein Structure, Tertiary
-
Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors
-
Proto-Oncogene Proteins c-mdm2 / metabolism*
-
Tumor Suppressor Protein p53 / antagonists & inhibitors
-
Tumor Suppressor Protein p53 / metabolism*
Substances
-
Amino Acids
-
Liposomes
-
Peptide Library
-
Peptides
-
Tumor Suppressor Protein p53
-
Proto-Oncogene Proteins c-mdm2